solid commerci pipelin
pipelin focal pt
rais sales/ep vs street
abbv share repo underlin
confid growth model eu humira biosimilar enter
loe eros rate in-lin abbv rate risa/
upad file posit launch ps/ra imbruvica/venclexta label
extens add leg growth mavyret us coverage/ex-
us launch bode well hcv target elagolix fda review liver
function data peg pdufa reiter pt
ep support dcf
rais oper execut repo fx tailwind
rais sales/ep street
rais hcv sale back robust
perform partial off-set lower humira sale
destock conserv assumpt co-pay accumul
discuss senior manag dutch auction share
repurchas indic deserv higher multipl best-in-group
growth outlook trade discount due humira concentr
risk pipelin risk demonstr uniqu knack build
franchis singl product purs maxim innov
pipelin within molecul strategi realiz humira imbruvica/venclexta
 pangenotyp hcv asset mavyret ideal posit launch
next-gener immunolog asset upadacitinib/ risankizumab
broad clinic develop plan advanc standard-of-car
respect indic expect see oper leverag
highli cash gener busi ep compound-annual-growth-rate vs
sale gener next five year put compani
strong posit shareholder-friendli capit alloc includ dividend
favorit large-cap valu name bristol-my squibb buy
buy one favorit large-cap/smidcap
growth name reiter pt ep support
dcf risk includ clinical/regulatori commerci execut around
imbruvica/venclexta data new use upadacitinib/risankizumab data/
tr target
file humira low-concentration/citrate-fre us formul launch well humira
humira share immunolog patient provid durabl
humira see strong commerci perform across differ geographi therapi area
us market humira maintain leadership across differ indic overal immunolog
market yoy growth rheumatolog rheum high-teen growth
dermatolog derm gastroenterolog gasto humira post volum growth
translat growth rheum growth derm gastro
humira key success vs innov next-gener asset signific leadership
market allow posit mainstay front-lin therapi humira maintain
share new patient depend indic howev next-gener asset
 cosentyx/taltz psoriasi releg second-lin therapi novarti share
earn call cosentyx nbrx share derm vs humira see
read-across note modestli lower us humira outlook yoy growth
impli growth factor pharmacy-level destock conserv
stanc co-pay cost associ co-pay accumul howev co-pay accumul repres
humira us volum legal front settl samsung bioepi
subsidiari samsung biolog rate rate expect
settl boehring ingelheim privat similar term see note ex-u market
alreadi put defens strategi place protect franchis perform europ
biosimilar enter octob view peak sale year ex-u humira
busi expect eros due biosimilar entri in-lin think
note earlier see note limit success biosimilar us/ex-u market make impli
street overestim eros humira ex-u market switch ex-u humira
patient new less pain lower volum /low burn citrate-fre formul make franchis
durabl lower humira sale vs street
maintain sale vs street
upad file track risa file await regulatori action
abbv next-gener asset upadacitinib upad oral inhibitor risankizumab risa
intraven subcutan inhibitor posit extend leadership global
immunolog market global immunolog market model assum global market grow
establish anti-tnf agent declin compound-annual-growth-rate
next-gen oral biolog grow although street extrapol potenti
concern rais fda adcom buy baracitinib olumi around thrombosi risk
upad note upad consist shown clean safeti profil result upad
fourth posit trial rheumatoid arthriti ra increas confid drug safety/efficaci
potenti see note plan submit nda applic upad ra
result fifth trial select-earli expect come month wait
result full clinic program report rate deep venou thrombosi dvt pulmonari
embol pe maintain rate within background rate ra patient overal
four ra trial instanc dvt/pe upad arm vs instanc
control arm upad also clinic develop cd uc atop
dermat ad readi model upad sale vs street abbv
set upda target full rang indic vs street
estim risankizumab shown unpreced efficaci four psoriasi phase trial result
superior humira click note abbvsubmit biolog licens applic bla
risankizumab treatment psoriasi fda apr assum fda action
plan submit risan regulatori file ema next day risa label expans
crohn diseas cd underway ulcer coliti uc initi later
psoriat arthriti trial underway add leg growth model risa sale
vs street abbv set risa target full rang indic vs
 street estim
hemonc steadi growth overlook street
imbruvica venclexta cement abbv leadership posit hem/onc market view
expect grow imbruvica broad label
leadership chronic lymphocyt leukemia cll market share cll
page
comprehens clinic develop program establish cornerston asset portfolio
note number imbruvica focus session june chicago includ
data waldenstrm macroglobulinemia trial abstract imbruvica opdivo
renal cell carcinoma captiv imbruvica venclexta cll also look
build-out imbruvica label includ interim result mantl cell lymphoma
shine follicular lymphoma selen imbruvica also rang studi
differ cll sub-popul young fit patient wait watch patient start
read model imbruvica sale in-lin abbv outlook
street sale imbruvica model vs street venclexta
unpreced murano data click note posit approval/ launch
relapsed/refractori cll expect venclexta grow tap untreat section r/r
cll without materi cannib imbruvica share indic also track file
venclexta acut myeloid leukemia aml late summer also expect data two
venclexta phase trial multipl myeloma mm one two trial focus
broader mm popul focus subset mm
patient patient overexpress transloc accord research publish
blood journal venclexta sale street
mavyret earli launch success exceed expect
mavyret pan-genotyp efficaci shorter durat therapi value-bas price discount
help exceed intern expect simultan beat our/street estim
total hcv sale exceed our/street number
respect month launch mavyret alreadi command share us hcv market
gain access cover live bulk access parity-contract
mavyret launch intern market japan germani spain itali also progress
well accord launch franc near-term hcv patient start us
japan expect declin low-teen yoy rate per gilead rate
present see exhibit howev expect mavyret continu grab share market
earli mavyret launch success gave confid rais hcv sale assumpt
recent present addit mavyret clinic data differ hcv set
easl see note support deeper penetr hcv market rais hcv
sale street estim
numer pipelin catalyst place upward pressur multipl
bounti catalyst drive out-perform settlement
 samsung bioepi allow compani launch biosimilar adalimumab oct
eu jan us expect settl biosimilar manufactur
near-term notabl boehring ingelheim plan submit nda applic
upadacitinib ra result fifth trial select-earli expect
come month abbvsubmit biolog licens applic bla risankizumab treatment
psoriasi fda apr assum fda action plan submit risan
regulatori file ema next day look import data read-out abbv
imbruvica/venclexta june chicago expect venclexta regulatori decis
relapsed/refractori cll base murano data catalyst venclexta includ
regulatori file aml late summer read-out two multipl myeloma trial fda
push elagolix endometriosi prioriti review assess liver function
test data think fda addit review elagolix data could support cleaner label see note
track releas elagolix uterin fibroid full data snda file track
next catalyst rova-t initi data phase basket studi neuro-endocrin
solid tumor data phase studi rova-t plu bmi opdivo yervoy sclc
abbv two rova-t pivot studi meru taho sclc continu enrol patient
data anticip
page
exhibit estim hepat viru hcv patient start
page
product rang rang rang rang midpoint strh estimatesconsensu total growth usnot growth ex-usnot peak sale assum biosimilar entri globalnot usnot viekira mavyret globalnot viekira mavyret us growth growth weight base approv r/r clllupron provid flat yoy flat provid flat yoy flat provid flat yoy flat incom totalnot provid approach fx impact fx marginnot sale sale provid marginnot expensenot ratenot rate rise next year rate lower due one-tim benefitnet incomenot providednot providednot providednot ep midpoint increas oper epsnot share outstand dilut providednot providednot providednot indic rang updat impli us ex-u rang abbvi inc
page
millionscurrentprior chg chg total non-oper expens incom dilut ep analysiscurrentprior chg chg bp gross changecurrentprior chg chg bp total millionscurrentprior chg chg total non-oper expens incom dilut ep analysiscurrentprior chg chg bp gross changecurrentprior chg chg bp total abbvi inc
exhibit estim strh vs consensu
page
exhibit pipelin strh vs consensu
page
exhibit in-lin product strh vs consensu
page
page
datecompanyproductev categoryev data releasephoenix phase ibr-rchop possibl submiss dlbcl combo w/ rchop data data cll imb gazyva vs chl gazyva data full data r/r fl vs br trial atop derm studi expect begin data full data dlbcl rchop vs rchop mabclin trial milestoneiniti evid biolog activ multipl data releaseuc phase biosimilarregulatoryema actionema action expect adalimumab biosimilar file accept file acut myeloid leukemia aml patient receiv high-dos induct therapyearli actionanticip approv elagolix endometriosi prioriti trial uc studi expect begin data basket studi neuroendocrin tumor data avail bmyrova-t/ opdivo yervoyclin data releasestart see data rova-t combin opdivo/ trial initiationiniti phase trial ulcer data ra select-earli data upadacitinib data r/r fl/mzl combo w/ br r-chop data data releas uterin data releas resolv data releasephas solid tumor data releas immerg r/r mm ibr actionregulatori approv expect base r/r cll murano broader label assetsclinicalind ind novel target trial initiationnsclc start pivot nsclc trial initiationnsclc start nsclc w/ data releas intellance-j data releas vela nsclc actionregulatori approv expect aml patient receiv high-dos induct therapi abbvi inc
page
datecompanyproductev categoryev actionfil pso base result immvent data releasefin data releas uterin submiss uterin data releasedata phase trial multipl myeloma data releas immpact data releas alliance-ctep data releasephas cll data releasephas data releas velia phase data meru trial first-lin small cell lung cancer data taho trial second-lin small cell lung cancer approv uterin data releasethre phase trial risankizumab crohn data cll gi data releas alliance-ctep cllnov trial uterin fibroid abbvi inc
page
 incom net ep ep outstand analysisgross changetot metricspric inc
page
assetscash tax -- -- -- -- -- -- -- -- -- -- -- prepaid current properti intang non-curr liabil short-term payabl accru matur lt current long-term non-curr equiti additon paid stock comprehens incom liabil abbvi inc
exhibit statement flow
page
flow oper activ net incom compens in-process asset liabil account cash use oper flow invest activ purchas properti invest net cash increas restrict cash increas market secur cash use invest flow financ activ proce repay short-term issuanc long-term long-term debt common stock option transact abbott laboratori -- -- -- -- -- -- -- -- -- -- -- -- -- dividend cash flow provid financ fx cash cash increas decreas cash cash cash equival begin cash equival end abbvi inc
inc highli focus research-driven biopharmaceut compani discov
develop deliv innov therapi treat health issu rang life-threaten ill
chronic condit gener total net sale sale deriv
us intern market compani core area expertis immunolog
hematology/oncolog virolog neurosci gener medicin
humira largest pharmaceut product histori biopharmaceut industri
total revenu come differ indic abbv second largest franchis hematology/
oncolog imbruvica/venclexta franchis account sale abbv
virolog franchis includ hepat product viekira/mavyret account
sale
rate buy one favorit valu name large-cap biopharmaceut
sinc launch believ time humira loss exclus us along
pipelin underappreci street thesi base humira us exclus
allow extract maximum valu franchis asset diversifi
revenu stream hematology/oncolog immunolog pipelin humira ideal
posit us volum driven growth price leverag well margin expans associ
expir upper single-digit royalti sale think evolv legal
regulatori landscap suggest us humira biosimilar competit delay januari
due long date humira patent estat global immunolog market model assum biosimilar
competit ex-u market late us earli legal catalyst around humira
play expect street push biosimilar entri us toward earli estim
put upward pressur street consensu humira sale estim
pipelin ideal posit view extern collabor intern
deriv asset provid next gener therapi autoimmun disord improv upon
humira best class profil posit leverag global humira infrastructur
pipelin immunolog asset includ upadacitinib select oral inhibitor risankizumab
monoclon antibodi target also posit reduc humira biosimilar risk
maxim hematology/oncolog franchis includ imbruvica venclexta hematolog
malign rova-t solid tumor model sales/ep cagr vs
street
valuat risk
price target assum trade ep premium major
biopharmaceut peer group expect abbv trade premium group settl
us patent disput humira pipelin matur multipl data read out immunolog
hematolog oncolog asset play model assum humira total sale account
sale immunolog hematology/oncolog sale new product
label expans exist asset rise sale
risk rate price target includ earlier expect humira biosimilar competit
us market addit assum compani abl gener revenu
pipelin lower humira total revenu clinic regulatori
commerci setback key pipelin asset upadacitinib risankizumab imbruvica venclexta rova-
elagolix etc could forc look extern acceler diversif sale prior
humira loss exclus us invest risk relat pharmaceut industri gener
includ continu price risk payer especi europ polit risk product develop
risk regulatori risk commerci risk legal risk patent challeng
compani mention note
compani buy john bori
rate
page
gilead rate
samsung biolog rate
john bori herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
